Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Sorry, I don't understand. Please try again

    1. Home/
    2. Media Center/
    3. Press releases /
    4. Medical technologies/
    5. Johnson & Johnson to Present 13 Abstracts Advancing Neurovascular Science at SVIN 2026

    Johnson & Johnson to Present 13 Abstracts Advancing Neurovascular Science at SVIN 2026

    Data from the MEMBRANE study and EXCELLENT registry expand the evidence base in chronic subdural hematoma and ischemic stroke

    Irvine, CA – November 17, 2026 – Johnson & Johnson today announced that 13 abstracts, including four podium presentations, will be featured at the Society of Vascular and Interventional Neurology (SVIN) 20th Annual Meeting in Las Vegas, Nevada. These abstracts span clinical studies, prospective registries, and real-world evidence (RWE), and examine patient outcomes in chronic subdural hematoma (cSDH) and ischemic stroke, including cognitive and other long-term clinical outcomes.

    A key focus of the scientific program is the evolving treatment landscape for cSDH, including middle meningeal artery embolization (MMAe). New analyses from the MEMBRANE study will explore important aspects of care for patients with cSDH and build on existing clinical data for TruFill n-BCA. These include an analysis of cognitive outcomes following MMAe, alongside additional investigations of treatment strategies and healthcare resource utilization.

    “Rigorous clinical evidence is essential to answering the questions that matter most in neurovascular care,” said Christian Cuzick, Worldwide President, Neurovascular, Johnson & Johnson MedTech. “From cognitive outcomes after MMAe in chronic subdural hematoma to large-population clot analysis, the research we’re presenting at SVIN is designed to inform everyday practice and help move patient care forward.”

    Beyond cSDH, the company will highlight research from the global EXCELLENT registry, a prospective study of 2,000 patients undergoing endovascular treatment for ischemic stroke with systematic clot analysis. Conducted across three continents, the registry examines differences in baseline characteristics, treatment practices, outcomes, and clot composition, contributing to a broader understanding of ischemic stroke management. The registry included first-line use of CEREGLIDE 71 and EMBOTRAP devices.

    Key presentations include:

    • Late-Breaking Presentation: The impact of middle meningeal artery embolization (MMAe) on cognitive outcomes: MEMBRANE Trial Post-hoc Analysis. Thursday, November 19. 10:30 a.m. PT, Dr. Fawaz Al-Muftii
    • E-Poster: TRUFILL n-BCA Middle Meningeal Artery Embolization from MEMBRANE Study: General Anesthesia versus Conscious Sedation. Dr. Jieqing Wanii
    • Poster: TRUFILL n-BCA Middle Meningeal Artery Embolization from MEMBRANE Study: Healthcare Resource Utilization among Surgically-Treated Patients. Wednesday, November 18. 8:00 a.m. PT, Dr. Charles C. Matoukiii
    • Oral Presentation: MEMBRANE: Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas with TRUFILL n-BCA – 12-Month Results. Friday, November 20. 8:00 a.m. PT, Dr. Christopher Kellneriv
    • Oral Presentation: The EXCELLENT Registry: A 2,000-Patient Prospective Global Registry of Endovascular Stroke Treatment with Systematic Clot Analysis. Friday, November 20. 8:00 a.m. PT, Dr. Raul Nogueirav

    In addition to scientific presentations, Johnson & Johnson will support early-career physician education through the SVIN Fellows Course and SVIN–SLICE Masterclass. The company will also spotlight TRUFILL n-BCA and the CEREGLIDE portfolio through hands-on sessions, clinical exchange and expert engagement at the Johnson & Johnson booth.

    About Cardiovascular Solutions from Johnson & Johnson MedTech
    Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary and peripheral artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit this website.

    About Johnson & Johnson
    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://www.jnjmedtech.com/. Follow us at @JNJMedTech and on LinkedIn.

    Cautions Concerning Forward-Looking Statements
    This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TRUFILL n-BCA, CEREGLIDE 71 and EMBOTRAP devices. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    References:
    i Dr. Al-Mufti served as a study investigator and as a consultant for Johnson & Johnson. Dr. Al-Mufti was not compensated for this authorship contribution.
    ii Dr. Wan served as a study investigator and as a consultant for Johnson & Johnson. Dr. Wan was not compensated for this authorship contribution.
    iii Dr. Matouk served as a study investigator and as a consultant for Johnson & Johnson. Dr. Matouk was not compensated for this authorship contribution.
    ivDr. Kellner served as a study investigator and as a consultant for Johnson & Johnson. Dr. Kellner was not compensated for this authorship contribution.
    v Dr. Nogueira served as a study investigator and as a consultant for Johnson & Johnson. Dr. Nogueira was not compensated for this authorship contribution.

    Media Contact:
    Erin Schlee
    ESchlee@ITS.JNJ.com

    Investor Contact:
    Sandra Easton
    Investor-relations@its.jnj.com